Zealand Pharma A/S Sustainability Profile
Zealand Pharma A/S, a leading biotechnology company headquartered in Denmark (DK), is renowned for its innovative approach to peptide-based therapeutics. Founded in 1998, the company has made significant strides in the biopharmaceutical industry, focusing on the development of novel treatments for diabetes, obesity, and gastrointestinal disorders. With a strong presence in Europe and North America, Zealand Pharma is committed to advancing its core products, which include unique peptide therapies that offer targeted solutions for complex health issues. The company has achieved notable milestones, including strategic partnerships and successful clinical trials, solidifying its position as a key player in the global biopharmaceutical market. Zealand Pharma's dedication to scientific excellence and patient-centric solutions continues to drive its growth and impact in the healthcare landscape.
DitchCarbon Score
How does Zealand Pharma A/S's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Zealand Pharma A/S's score of 47 is higher than 65% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Zealand Pharma A/S's reported carbon emissions
In 2024, Zealand Pharma A/S reported total carbon emissions of approximately 266,557,000 kg CO2e. This figure includes 145,000 kg CO2e from Scope 1 emissions, 17,000 kg CO2e from Scope 2 emissions (location-based), and a significant 266,412,000 kg CO2e from Scope 3 emissions. The Scope 3 emissions breakdown reveals major contributions from purchased goods and services (42,712,000 kg CO2e), investments (6,219,000 kg CO2e), and employee commuting (254,000 kg CO2e). In 2023, the company recorded total emissions of about 73,923,000 kg CO2e, with Scope 1 emissions at 144,000 kg CO2e, Scope 2 emissions at 56,000 kg CO2e (location-based), and Scope 3 emissions reaching 73,757,000 kg CO2e. This indicates a substantial increase in emissions from 2023 to 2024. Zealand Pharma has committed to achieving net-zero emissions, as indicated by their status with the Science Based Targets initiative (SBTi). They are currently classified as "Committed" to near-term targets, although specific reduction targets have not been disclosed. The company operates within the pharmaceuticals, biotechnology, and life sciences sector and is headquartered in Denmark (DK). Overall, Zealand Pharma's emissions data reflects a significant reliance on Scope 3 emissions, highlighting the importance of addressing supply chain and operational impacts in their climate strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | - | - | 000,000 | 000,000 |
| Scope 2 | - | - | 00,000 | - |
| Scope 3 | - | - | 00,000,000 | 000,000,000 |
How Carbon Intensive is Zealand Pharma A/S's Industry?
How Carbon Intensive is Zealand Pharma A/S's Location?
Zealand Pharma A/S's Scope 3 Categories Breakdown
Zealand Pharma A/S's Scope 3 emissions, which increased by 261% last year and increased by approximately 261% since 2023, demonstrating supply chain emissions tracking. Nearly all of their carbon footprint comes from suppliers and value chain emissions, representing nearly all emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 16% of Scope 3 emissions.
Top Scope 3 Categories
Zealand Pharma A/S's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Zealand Pharma A/S has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Frequently Asked Questions
Common questions about Zealand Pharma A/S's sustainability data and climate commitments
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.